Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells $81,519.42 in Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Michael Patrick Miller sold 23,358 shares of the firm’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $3.49, for a total value of $81,519.42. Following the completion of the sale, the director now directly owns 47,000 shares in the company, valued at approximately $164,030. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Puma Biotechnology Stock Performance

PBYI stock traded up $0.15 during midday trading on Tuesday, reaching $3.61. 148,720 shares of the company’s stock traded hands, compared to its average volume of 505,316. The company has a 50-day moving average price of $3.44 and a two-hundred day moving average price of $4.58. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.23 and a current ratio of 1.32. Puma Biotechnology, Inc. has a 52 week low of $2.13 and a 52 week high of $7.73. The firm has a market capitalization of $174.14 million, a PE ratio of 10.94 and a beta of 1.09.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $47.10 million during the quarter, compared to analyst estimates of $43.99 million. Puma Biotechnology had a net margin of 4.01% and a return on equity of 18.36%. During the same period in the prior year, the business posted $0.05 earnings per share. As a group, equities analysts anticipate that Puma Biotechnology, Inc. will post 0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on PBYI. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, August 2nd.

Institutional Investors Weigh In On Puma Biotechnology

A number of hedge funds have recently modified their holdings of PBYI. Victory Capital Management Inc. purchased a new stake in Puma Biotechnology in the 2nd quarter worth $54,000. SG Americas Securities LLC bought a new position in Puma Biotechnology in the 1st quarter worth about $57,000. Crestline Management LP boosted its stake in shares of Puma Biotechnology by 6.5% during the fourth quarter. Crestline Management LP now owns 34,774 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 2,135 shares in the last quarter. Rhumbline Advisers lifted its position in Puma Biotechnology by 2,309.9% during the second quarter. Rhumbline Advisers now owns 50,270 shares of the biopharmaceutical company’s stock valued at $164,000 after acquiring an additional 48,184 shares during the last quarter. Finally, Jump Financial LLC lifted its position in Puma Biotechnology by 131.7% during the fourth quarter. Jump Financial LLC now owns 57,200 shares of the biopharmaceutical company’s stock valued at $248,000 after acquiring an additional 32,510 shares during the last quarter. Institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.